Blog Posts

SECOND OPINION: LATEST PHRMA AD CAMPAIGN DEFENDS PATENT ABUSE “STATUS QUO”

Jun 26, 2024

Big Pharma Advertising Blitz Seeks to Protect Anti-Competitive Tactics That Read More

DOSE OF REALITY: FORBES: HOW BIG PHARMA EXPLOITS LOOPHOLES IN THE PATENT SYSTEM

Jun 25, 2024

Avik Roy Highlights How Increased USPTO-FDA Collaboration and Greater Scrutiny Read More

DOSE OF REALITY: FORBES: HOW BIG PHARMA STIFLES COMPETITION WITH PRODUCT SHOPPING

May 23, 2024

Research Column Explores Case Study in Common Patent Abuse Tactic That Read More

DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE BLOCKS COMPETITION IN THE PRESCRIPTION DRUG MARKET, KEEPS DRUG PRICES HIGH

May 21, 2024

Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold Read More

DOSE OF REALITY: STUDY FINDS NEARLY THREE-QUARTERS OF BIG PHARMA’S PATENTS ON TOP-SELLING DRUGS FILED AFTER FDA APPROVAL

May 16, 2024

Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on Read More

DOSE OF REALITY: IQVIA REPORT SHOWS HOW BIG PHARMA’S EGREGIOUS PRICING PRACTICES DRIVE INCREASED PRESCRIPTION DRUG SPENDING

May 10, 2024

Analysis Shows Price Hikes Outpacing Inflation, Rising Launch Prices and Read More

BIG PHARMA EARNINGS WATCH: ELI LILLY, NOVO NORDISK, ABBVIE, AMGEN, GLAXOSMITHKLINE AND PFIZER

May 6, 2024

Repeated Price Hikes and Egregious Prices on GLP-1 Weight Loss Drugs Boost Read More

DOSE OF REALITY: BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM

May 2, 2024

Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics Read More

BIG PHARMA EARNINGS WATCH: NOVARTIS, MERCK, ASTRAZENECA, BRISTOL MYERS SQUIBB AND SANOFI

Apr 26, 2024

Big Pharma Continues Raking in Big Profits and Expectation-Beating Revenue Read More